INVASIVE LOBULAR CARCINOMAS TREATED AT HOSPITAL DE CLÍNICAS OF UFPR
INCIDENCE, CHARACTERISTICS AND CLINICAL OUTCOME
Keywords:
lobular carcinoma, breast neoplasms, histology, ductal carcinoma, medullary carcinomaAbstract
Objective: The aim of this study is to depict the clinical and epidemiological profile of patients treated for invasive lobular carcinoma (ILC) at Hospital das Clínicas of Universidade Federal do Paraná (HC-UFPR) over the course of ten years and to evaluate the variation of ILC dimensions on imaging exams by comparing them to real-size lesions identified in surgical specimens. Methods: Patients undergoing breast surgical procedures at HC-UFPR from 2005 to 2014 were selected. Out of these, 36 were diagnosed with ILC and had their medical files sought after clinical, epidemiological, therapeutic and prognosis characteristics. The variance of tumor sizes in imaging methods and anatomopathological descriptions were also studied. Results: Patients’ mean age at diagnosis was 59.6 years. Most of them were classified as clinical stages II (40%) and III (26.7%) by the time they were diagnosed. The majority of tumors were HER2 negative (77.2%) and estrogen-receptor positive (90%). The surgical treatment was radical in 74.2% of the cases. 31.4% of the patients underwent both mammography and ultrasonography screening and 45.7% underwent only one of them. None of the patients were submitted to magnetic resonance imaging (MRI). Conclusion: Data found about patients with invasive lobular carcinoma at HC-UFPR is in accordance with the medical literature, including incidence rates and tumor characteristics. The variance of tumor sizes in imaging exams and surgical specimen was not statistically significant.
Downloads
References
Instituto Nacional de Cancer José Alencar Gomes da Silva. Estimativa 2016. Brasil: Ministério da Saúde; 2016.
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC cancerbase. cancer incidence and mortality worldwide. IARC Cancer Base; 2014.
Li CI, Uribe DJ, Daling JR. Clinical characteristics of different histologic types of breast cancer. Br J Cancer. 2005;93(9):1046‑52.https://dx.doi.org/10.1038%2Fsj.bjc.6602787
Dossus L, Benusiglio PR. Lobular breast cancer: incidence and genetic and non-genetic risk factors. Breast Cancer Res. 2015;17:37. https://doi.org/10.1186/s13058-015-0546-7
Eheman CR, Shaw KM, Ryerson AB, Miller JW, Ajani UA, White MC. The changing incidence of in situ and invasive ductal and lobular breast carcinomas: United States, 1999-2004. Cancer Epidemiol Biomarkers Prev. 2009;18(6):1763-9. https://doi.org/10.1158/1055-9965.EPI-08-1082
Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women. J Am Med Assoc. 2012;288(3):321-33.
Wachtel MS, Yang S, Dissanaike S, Margenthaler JA. Hormone replacement therapy, likely neither angel nor demon. PLoS One. 2015;10(9):e0138556. https://doi.org/10.1371/journal.pone.0138556
Christgen M, Steinemann D, Kühnle E, Länger F, Gluz O, Harbeck N, et al. Lobular breast cancer: Clinical, molecular and morphological characteristics. Pathol Res Pract. 2016;212(7):583-97. https://doi.org/10.1016/j.prp.2016.05.002
Allen-Brady K, Camp NJ, Ward JH, Cannon-Albright LA. Lobular breast cancer: Excess familiality observed in the Utah Population Database. Int J Cancer. 2005;117(4):655-61. https://doi.org/10.1002/ijc.21236
Li CI, Daling JR, Haugen KL, Tang MTC, Porter PL, Malone KE. Use of menopausal hormone therapy and risk of ductal and lobular breast cancer among women 55-74 years of age. Breast Cancer Res Treat. 2014;145(2):481-9. https://doi.org/10.1007/s10549-014-2960-4
Newcomb PA, Trentham-Dietz A, Hampton JM, Egan KM, Titus-Ernstoff L, Warren Andersen S, et al. Late age at first full term birth is strongly associated with lobular breast cancer. Cancer. 2011;117(9):1946-56. https://dx.doi.org/10.1002%2Fcncr.25728
Li CI, Malone KE, Porter PL, Weiss NS, Tang MTC, Daling JR. Reproductive and anthropometric factors in relation to the risk of lobular and ductal breast carcinoma among women 65-79 years of age. Int J Cancer. 2003;107(4):647-51. https://doi.org/10.1002/ijc.11465
Sharma SDJ, Barry M, O’Reilly EA, Kell MR. Surgical management of lobular carcinoma from a national screening program: a retrospective analysis. Eur J Surg Oncol. 2015;41(1):79-85. https://doi.org/10.1016/j.ejso.2014.09.004
Lee J-H, Park S, Park HS, Park B-W. Clinicopathological features of infiltrating lobular carcinomas comparing with infiltrating ductal carcinomas: a case control study. World J Surg Oncol. 2010;8:34. https://doi.org/10.1186/1477-7819-8-34
Arpino G, Bardou VJ, Clark GM, Elledge RM. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res. 2004;6(3):R149-56. https://dx.doi.org/10.1186%2Fbcr767
Sastre-Garau X, Jouve M, Asselain B, Vincent-Salomon A, Beuzeboc P, Dorval T, et al. Infiltrating lobular carcinoma of the breast: Clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns. Cancer. 1996;77(1):113-20. https://doi.org/10.1002/(SICI)1097-0142(19960101)77:1%3C113::AIDCNCR19%3E3.0.CO;2-8
Sinclair K, Sakellariou S, Dawson N, Litherland J. Does preoperative breast MRI significantly impact on initial surgical procedure and re-operation rates in patients with screen-detected invasive lobular carcinoma? Clin Radiol. 2016;71(6):543-50. https://doi.org/10.1016/j.crad.2016.03.011
Smith DB, Howell A, Wagstaff J. Infiltrating lobular carcinoma of the breast: Response to endocrine therapy and survival. Eur J Cancer Clin Oncol. 1987;23(7):979-82.
Dutra MC, Rezende MA, de Andrade VP, Soares FA, Ribeiro MV, de Paula EC, et al. Imunofenótipo e evolução de câncer de mama: comparação entre mulheres muito jovens e mulheres na pós-menopausa. Rev Bras Ginecol Obs. 2009;31(2):54-60. http://dx.doi.org/10.1590/S0100-72032009000200002
Biglia N, Mariani L, Sgro L, Mininanni P, Moggio G, Sismondi P. Increased incidence of lobular breast cancer in women treated with hormone replacement therapy: implications for diagnosis, surgical and medical treatment. Endocr Relat Cancer. 2007;14(3):549-67. https://doi.org/10.1677/ERC-06-0060
Zhu MZ, Yu XF, He XM, Feng WL, Fan JH, Li J, et al. Clinicopathological features of invasive lobular carcinoma of the breast: a nationwide multicenter study in China. J Cancer Res Ther. 2015;11(Supl. 1):C89-94. https://doi.org/10.4103/0973-1482.163851
Winchester DJ, Chang HR, Graves TA, Menck HR, Bland KI, Winchester DP. A comparative analysis of lobular and ductal carcinoma of the breast: presentation, treatment, and outcomes. J Am Coll Surg. 1998;186(4):416-22.
Gomes, DS. Aspectos clínicos, anátomo-patológicos e evolutivos de uma série de lesões lobulares da mama tratadas em uma mesma instituição [dissertation]. Belo Horizonte: Federal University of Minas Gerais. Medicine School; 2010;
Peiro G, Bornstein BA, Connolly JL, Gelman R, Hetelekidis S, Nixon AJ, et al. The influence of infiltrating lobular carcinoma on the outcome of patients treated with breast-conserving surgery and radiation therapy. Breast Cancer Res Treat. 2000;59(1):49-54.
Dillon MF, Hill ADK, Fleming FJ, O’Doherty A, Quinn CM, McDermott EW, et al. Identifying patients at risk of compromised margins following breast conservation for lobular carcinoma. Am J Surg. 2006;191(2):201-5. https://doi.org/10.1016/j.amjsurg.2005.03.041
Salles MDA, Cúrcio VS, Perez AA, Gomes DS, Gobbi H. Contribuição da imuno-histoquímica na avaliação de fatores prognósticos e preditivos do câncer de mama e no diagnóstico de lesões mamárias. J Bras Patol e Med Lab. 2009;45(3):213-22. http://dx.doi.org/10.1590/S1676-24442009000300006
Giuliano AE, Ballman K, McCall L, Beitsch P, Whitworth PW, Blumencranz P, et al. Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases. Ann Surg. 2016;264(3):413-20. https://doi.org/10.1097/SLA.0000000000001863
Rakha EA, El-Sayed ME, Powe DG, Green AR, Habashy H, Grainge MJ, et al. Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes. Eur J Cancer. 2008;44(1):73-83. https://doi.org/10.1016/j.ejca.2007.10.009
Mann RM, Hoogeveen YL, Blickman JG, Boetes C. MRI compared to conventional diagnostic work-up in the detection and evaluation of invasive lobular carcinoma of the breast: a review of existing literature. Breast Cancer Res Treat. 2008 Jan;107(1):1-14. https://dx.doi.org/10.1007%2Fs10549-007-9528-5
Yeatman TJ, Cantor AB, Smith TJ, Smith SK, Reintgen DS, Miller MS, et al. Tumor biology of infiltrating lobular carcinoma. Implications for management. Ann Surg. 1995;222(4):549-61.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2018 Anaí Caroline Hamann Gasperin, Gabriela Romaniello, Isabella Naomi Furuie, Maria Júlia Jorge Mauro, Thayane Guimarães de Melo, Plínio Gasperin Júnior, Vinicius Milani Budel
This work is licensed under a Creative Commons Attribution 4.0 International License.
